**Background**

Glucocorticoids are a class of steroid hormones that play a pivotal role in regulating immune responses and maintaining homeostasis. In particular, the modulation of the Notch signaling pathway has emerged as a critical mechanism for treating various autoimmune and inflammatory conditions. Dysregulation of this pathway can lead to an imbalance in T-cell subsets, contributing to diseases such as autoimmune uveitis, or impact cognitive functions through the modulation of synaptic plasticity in the hippocampus. Understanding the interplay between glucocorticoid activity and Notch signaling is essential for developing targeted therapies for immune-mediated disorders and neurological impairments. In this context, we will introduce a potent glucocorticoid and orally active Notch inhibitor – Prednisone.

**Definition**

Prednisone (specifically Prednisone acetate) is a glucocorticoid and orally active Notch inhibitor with a molecular weight of 400.46 and the chemical formula C23H28O6. It targets IL-17, IL-10, and IL-4 to modulate immune responses.

**In Vivo Studies**

The Prednisone biological activity has been extensively evaluated in various animal models to determine its effects on the immune system and cognitive function. In a study involving C57BL/6 mice, Prednisone acetate (5 mg/kg; intragastric gavage; once daily for 4 weeks) was used to induce hippocampal long-term potentiation (LTP) impairment. The results showed that the treatment caused neuronal lesions in the dentate gyrus, reduced the levels of glutamic acid (Glu) and gamma-aminobutyric acid (GABA), and decreased the expression of N-methyl-D-aspartate receptors (NMDAR2A) in the hippocampus. This led to a significant reduction in population spikes after high-frequency stimulation and impaired spatial memory, as evidenced by reduced crossing times compared to the control group.

Furthermore, Prednisone in vivo studies in rats with experimental autoimmune uveitis (EAU) demonstrated its anti-inflammatory potential. Administration of Prednisone acetate (6 mg/kg; gavage; once daily for 15 days) reduced ocular and peripheral inflammatory responses. The compound bound with high affinity to the pocket of Notch signaling-related molecules, inhibiting Notch activation and restoring Th1/Th2 and Th17/Treg immune homeostasis by decreasing Th1 and Th17 frequencies while increasing Th2 and Treg frequencies. According to the Prednisone technical information, these results highlight its dual role in modulating both neurological plasticity and systemic inflammation. In conclusion, Prednisone is a versatile glucocorticoid that acts as a Notch inhibitor to regulate immune homeostasis and influence hippocampal function.

Keywords

Prednisone, 125-10-0, Prednisone 21-acetate, Glucocorticoid Receptor, Interleukin Related, Notch, IL, Hippocampus, Experimental autoimmune uveitis, Inhibitor, inhibitor, inhibit

References

[1] Prednisolone acetate
[2] Wang Y, et al. Intragastric administration of prednisone acetate induced impairment of hippocampal long-term potentiation [J]. Brain Research, 2023, 1805: 148270.
[3] Zhou M, Qu R, Yin X, et al. Prednisone acetate modulates Th1/Th2 and Th17/Treg cell homeostasis in experimental autoimmune uveitis via orchestrating the Notch signaling pathway [J]. International Immunopharmacology, 2023, 116: 109809.

**Background**

Vaginal candidiasis is a common fungal infection caused primarily by Candida albicans and other Candida species. These opportunistic pathogens can cause significant inflammation, itching, and discomfort, impacting the quality of life for a large number of women. The management of these infections requires potent antifungal agents capable of disrupting the fungal cell membrane to eliminate the pathogen. Imidazole derivatives have long been utilized in clinical settings due to their ability to interfere with the biosynthesis of essential fungal sterols. In this context, we will introduce an imidazole antifungal agent – Butoconazole.

**Definition**

Butoconazole is an imidazole antifungal agent active against Candida spp., specifically effective against vaginal infections caused by Candida albicans.

**Mechanism of Action**

According to the Butoconazole description, this compound is presumed to function similarly to other imidazole derivatives via the inhibition of steroid synthesis. Specifically, Butoconazole in vitro activity involves the inhibition of the conversion of lanosterol to ergosterol. This enzymatic blockade results in a significant change in the lipid composition of the fungal cell membrane. Such structural alterations increase cell permeability, which ultimately leads to the osmotic disruption or growth inhibition of the fungal cell. For researchers requiring specific Butoconazole technical information, these mechanisms highlight its utility in studying fungal membrane dynamics.

**In Vitro Studies**

The pharmacological profile of Butoconazole is characterized by its ability to target the fungal cell wall. While specific IC50 values for various strains are not provided, it is established that the compound effectively inhibits the growth of Candida albicans by altering membrane integrity. The Butoconazole Formula (C19H18Cl3N3O3S) and its molecular weight of 474.79 contribute to its stability and efficacy as a topical antifungal agent. In conclusion, Butoconazole is a potent imidazole antifungal agent that serves as a critical tool for research into the treatment of Candida-induced infections.

Keywords

Butoconazole, 64872-77-1, RS 35887, RS35887, RS-35887, Fungal, Inhibitor, inhibitor, inhibit

References

[1] Anik ST, et al. Extreme vertexes design in formulation development: solubility of butoconazole nitrate in a multicomponent system. J Pharm Sci. 1981;70(8):897-900.
[2] Pharmacology refers to the chemical makeup and behavior of GYNAZOLE 1 (butoconazole nitrate cream).

**Background**

Breast cancer remains a significant global health challenge, characterized by high recurrence rates and the potential for metastasis. The aldehyde dehydrogenase (ALDH) family of enzymes, particularly ALDH1A, plays a critical role in cellular detoxification and the maintenance of cancer stem cells, making them attractive targets for therapeutic intervention. Beyond oncology, chronic inflammation and associated pain, such as that seen in pleurisy or endometritis, require effective agents that can modulate immune responses and prevent tissue damage. Finding natural compounds that exhibit both antitumor and anti-inflammatory properties is a key focus of biomedical research. In this context, we will introduce a natural monoterpene compound – Citral.

**Definition**

Citral is an orally active monoterpene found in lemon grass essential oil that serves as a natural ALDH1A inhibitor.

**In Vitro and In Vivo Studies**

According to the Citral description, this compound is classified as a ketone/aldehyde with the Citral Formula $\text{C}_{10}\text{H}_{16}\text{O}$. Citral biological activity has been extensively studied across various models. Citral in vitro studies demonstrate that the compound (10, 50, 100 $\mu\text{g/mL}$; 72 h) exhibits no cytotoxicity toward J774 macrophages. However, it shows significant potency against breast cancer cells; specifically, Citral (0-0.5 $\mu\text{M}$; 72 h) inhibits cell proliferation and induces apoptosis and cell cycle arrest in the MCF-7 breast cancer cell line. Similarly, Citral (0-100 $\mu\text{g/mL}$; 72 h) exhibits anti-proliferative and pro-apoptotic activities in the MDA-MB-231 breast cancer cell line, highlighting its potential in Citral Cancer research.

Citral In Vivo evaluations have further revealed its therapeutic versatility. In adult male Swiss mice with pleurisy, Citral (100 mg/kg; p.o.) improved anti-hyperalgesic and anti-inflammatory activities, resulting in reduced white blood cell counts and decreased TNF-$\alpha$ expression levels. Furthermore, in female BALB/c mice, Citral (10, 20, 40 mg/kg; i.p.) was found to prevent LPS-induced endometritis by activating the Nrf2 signaling pathway and inhibiting ferroptosis, thereby attenuating uterine pathological damage and inflammation. In conclusion, Citral is a natural ALDH1A inhibitor with potent anti-cancer, anti-inflammatory, and analgesic properties.

Keywords

Citral, 5392-40-5, Parasite, analgesic, anti-inflammatory, MCF-7 cell, MDA-MB-231 cell, Inhibitor, inhibitor, inhibit

References

[1] Campos CA, et al. Anti-hyperalgesic and anti-inflammatory effects of citral with β-cyclodextrin and hydroxypropyl-β-cyclodextrin inclusion complexes in animal models. Life Sci. 2019 Jul 15;229:139-148.
[2] Chaouki W, et al. Citral inhibits cell proliferation and induces apoptosis and cell cycle arrest in MCF-7 cells. Fundam Clin Pharmacol. 2009 Oct;23(5):549-56.
[3] Souza ACS, et al. Citral presents cytotoxic and genotoxic effects in human cultured cells. Drug Chem Toxicol. 2020 Jul;43(4):435-440.
[4] Zhao W, et al. Citral protects against LPS-induced endometritis by inhibiting ferroptosis through activating Nrf2 signaling pathway. Inflammopharmacology. 2023 Jun;31(3):1551-1558.

**Background**

CD47 is a transmembrane protein widely expressed on the surface of various cells, including healthy cells and tumor cells. It acts as a “don’t eat me” signal by interacting with signal regulatory protein alpha (SIRPα) on macrophages, thereby inhibiting phagocytosis and allowing cancer cells to evade the innate immune system. This immune evasion mechanism is a critical factor in tumor progression and metastasis across various malignancies. Consequently, blocking the CD47-SIRPα axis has emerged as a promising therapeutic strategy to enhance macrophage-mediated clearance of tumor cells. In this context, we will introduce an Anti-CD47 Antibody description – Anti-CD47 Antibody (B6.H12).

**Definition**

Anti-CD47 Antibody (B6.H12) is a mouse IgG1 κ chimeric antibody that specifically targets human CD47 to block its interaction with SIRPα.

**In Vitro and In Vivo Studies**

The Anti-CD47 Antibody biological activity has been extensively evaluated across multiple cancer models. In vitro, Anti-CD47 Antibody (B6.H12) (10 μg/mL, 2 h) significantly increases the macrophage phagocytosis of HepG2, H3B, meningioma, and osteosarcoma tumor cells. Furthermore, it demonstrates potent inhibitory effects on tumor cell behavior; specifically, it decreases the proliferation of IOMM-Lee cells (10 μg/mL, 2 h) and attenuates their migration and invasion abilities (10 μg/mL, 24 h). In osteosarcoma cells, a concentration of 100 μg/mL over 5 days significantly decreases invasion. Notably, the antibody (1.1-10 μg/mL, 24-72 h) is not cytotoxic to normal hepatocytes or human hepatocellular carcinoma cells.

Regarding Anti-CD47 Antibody in vivo performance, the antibody shows potent anti-tumor effects in various xenograft models. In heterotopic and orthotopic tumor mice models, administration of 400 μg (i.p., twice weekly) inhibited tumor growth and increased the intra-tumor migration of macrophages. In nude mice injected with IOMM-Lee cells, 100 μg (i.p., daily for 5 weeks) resulted in significantly smaller tumor volumes. Additionally, in osteosarcoma mice models, 100 μg (i.p., three times weekly) inhibited tumor progression and reduced the incidence of spontaneous metastasis. In conclusion, Anti-CD47 Antibody (B6.H12) is a powerful tool for Anti-CD47 Antibody Cancer research, effectively promoting phagocytosis and inhibiting tumor growth.

Keywords

Anti-CD47 Antibody (B6.H12), CD47, Cluster of Differentiation 47, MER6, OA3, SIRPα, Proliferation, Macrophage, Cancer, Osteosarcoma, IOMM-Lee, Inhibitor, inhibitor, inhibit

References

[1] Xiao Z, et al. Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinoma. Cancer Lett. 2015 May 1;360(2):302-9.
[2] Liu X, et al. Tumor-selective Blockade of CD47 Signaling with CD47 Antibody for Enhanced Anti-tumor Activity in Malignant Meningioma. Curr Neuropharmacol. 2023;21(10):2159-2173.
[3] Xu JF, et al. CD47 blockade inhibits tumor progression human osteosarcoma in xenograft models. Oncotarget. 2015 Sep 15;6(27):23662-70.

**Background**

Benign prostatic hyperplasia (BPH) is a common condition characterized by the nonmalignant growth of the prostate gland, which often leads to lower urinary tract symptoms and impaired bladder emptying. Similarly, hypertension remains a global health challenge, requiring effective pharmacological interventions to reduce blood pressure and prevent cardiovascular complications. The $\alpha_1$-adrenoceptor plays a critical role in regulating the smooth muscle tone of both blood vessels and the bladder neck. By antagonizing these receptors, it is possible to relax the vascular system and open the bladder, providing therapeutic relief for patients with these conditions. In this context, we will introduce an orally active $\alpha_1$-adrenoceptor antagonist – Terazosin.

**Definition**

Terazosin is a quinazoline derivative that acts as a competitive $\alpha_1$-adrenoceptor antagonist. According to the Terazosin technical information, this compound is utilized to treat high blood pressure and BPH by relaxing smooth muscles in the blood vessels and the bladder.

**In Vitro and In Vivo Studies**

The Terazosin description highlights its utility across various experimental models. In terms of Terazosin in vitro activity, studies using COS cells have demonstrated that Terazosin does not discriminate between cloned $\alpha_1$-adrenoceptor subtypes that are transiently expressed. This suggests a broad antagonistic effect across the $\alpha_1$ receptor family.

Regarding Terazosin In Vivo applications, the compound has been investigated for its ability to promote stone discharge in the treatment of ureteral stones. Specifically, research indicates that Terazosin is safe and effective for the treatment of distal ureteral stones, particularly those with a diameter greater than 5 mm. Furthermore, combination therapies involving Terazosin and nifedipine have been explored to enhance postoperative outcomes following transurethral ureteroscopic lithotripsy. In conclusion, Terazosin is a potent $\alpha_1$-adrenoceptor antagonist with significant potential for treating BPH, hypertension, and distal ureteral stones.

Keywords

Terazosin, 63074-08-8, Adrenergic Receptor, Beta Receptor, α1-adrenoceptor, benign, prostatic, hyperplasia, high, blood, pressure, bladder, quinazoline, Inhibitor, inhibitor, inhibit

References

[1] Michel MC, et al. Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned alpha 1-adrenoceptor subtypes and in human prostate. J Auton Pharmacol. 1996 Feb;16(1):21-8.
[2] Vincent J, et al. Pharmacological tolerance to alpha 1-adrenergic receptor antagonism mediated by terazosin in humans. J Clin Invest. 1992 Nov;90(5):1763-8.
[3] Ju M, et al. Efficacy of combination terazosin and nifedipine therapy in postoperative treatment of distal ureteral stones after transurethral ureteroscopic lithotripsy. J Int Med Res. 2020 Apr;48(4):300060520904851.